What Will Happen to FSD PHARMA INC (OTCMKTS:FSDDF) Next? The Stock Has Decline in Shorts

The stock of FSD PHARMA INC (OTCMKTS:FSDDF) registered a decrease of 47.19% in short interest. FSDDF’s total short interest was 16,900 shares in December as published by FINRA. Its down 47.19% from 32,000 shares, reported previously.

The stock increased 0.14% or $0.0003 during the last trading session, reaching $0.2403. About 303,923 shares traded. FSD Pharma Inc. (OTCMKTS:FSDDF) has 0.00% since December 8, 2017 and is . It has underperformed by 15.62% the S&P500.

FSD Pharma Inc. operates as a cannabis firm in Canada. The company has market cap of $320.52 million. It is involved in hydroponic indoor cannabis production and processing activities. It currently has negative earnings. The company, through its subsidiary, FV Pharma Inc., holds license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations.

More notable recent FSD Pharma Inc. (OTCMKTS:FSDDF) news were published by: Investorideas.com which released: “Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: NASDAQ: $TLRY, CSE: $HUGE.C, CSE: $AUSA.C, TSX: $ACB.TO, CSE: $CGOC.C, TSV: $NV – InvestorIdeas.com” on September 19, 2018, also Seekingalpha.com with their article: “FSD Pharma inks deal with Canntab for production and market of oral dose delivery platforms – Seeking Alpha” published on September 18, 2018, Seekingalpha.com published: “The Most Popular Marijuana ETF Just Added These 9 Stocks (2/2) – Seeking Alpha” on October 03, 2018. More interesting news about FSD Pharma Inc. (OTCMKTS:FSDDF) were released by: Seekingalpha.com and their article: “FSD Pharma reports positive pre-clinical results for CBD combination product – Seeking Alpha” published on August 23, 2018 as well as Seekingalpha.com‘s news article titled: “FSD Pharma nabs cannabis license in Canada – Seeking Alpha” with publication date: October 25, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.